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Atrial fibrillation (AF) ablation has historically been guided by fluoroscopy, with the related 
enhanced risk deriving from radiation. Fluoroscopy exposure may be confined to guide the 
transseptal puncture. Small sample size study presented a new methodology to perform a totally 
fluoroless AF ablation in case of a patent foramen ovale (PFO). We evaluated this methodology in a 
large sample size of patients and a multicenter experience. 
Methods and Results 
Two-hundred fifty Paroxysmal AF patients referred for first AF ablation with CARTO3 
electroanatomic mapping system were enrolled. In 58/250 a PFO allowed crossing of the interatrial 
septum, and a completely fluoroless ablation was performed applying the new method (Group A). 
In the remaining patients a standard transseptal puncture was performed (Group B). Pulmonary vein 
isolation was achieved in all patients with comparable procedural and clinical outcomes at short and 
long-term follow-up. 
Conclusion 
The presence of a PFO may allow a completely fluoroless safe and effective AF ablation. Probing 
the fossa ovalis looking for the PFO during the procedure is desirable since it is not time consuming 
and can potentially be done in every patient undergoing AF ablation. 
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X-ray fluoroscopy has conventionally been used to guide electrophysiology procedures, exposing 
patients and operators to the stochastic and deterministic effects of radiations (1-5). 
Since the number of atrial fibrillation (AF) ablations has increased substantially over recent years, 
making AF procedures the most commonly encountered ablation in clinical practice, fluoroscopy 
exposure to patients and particularly electrophysiologists is considerable over time. Despite the 
widespread of 3D mapping systems, which dramatically reduced X-ray exposure, fluoroscopy is 
still considered a necessary tool for various steps in the ablation procedure, such as performance of 
the transseptal puncture (6-9). 
There is growing evidence that catheter ablation of AF is feasible using various techniques to 
reduce or eliminate fluoroscopy, such as integration of 3D mapping systems with fluoroscopy 
images and combination with intracardiac echocardiography (ICE) to guide the transseptal puncture 
(10,11,12). Despite these promising results, we have to consider that ICE still requires a dedicated 
operator, an additional venous puncture, potentially increasing the risk of vascular complications, 
can result in longer ablation procedures and may increase the cost of the procedure. 
We already demonstrated that performing an AF ablation with a very limited X-ray exposure is 
feasible when using a 3D electroanatomic mapping (EAM) system. In our previous experience, our 
mean X-ray time was 2.28 ± 1.40 minutes indeed and it was mainly confined to manage the 
transseptal puncture (13). 
Based on this consideration fluoroscopy in AF ablation may be strictly confined to guide the 
transseptal puncture.  
Our electrophysiological center started a program dedicated to reduce the X ray exposure early in 
2008 using the 3D EAM system that was then carried out through the years (10,11,12). Based on 
this experience we decided to evaluate prospectively, from June 2014 in a multicenter study,  the 




meanwhile in 2016 Kuhne et al (14) published a small sample size single center similar experience. 
As usual, several centers, may be focused on the same topic at the same time. Once published the 
experience by Kuhne et al, our ongoing study was not modified because it was reaching the end of 
the enrollment period. Therefore we thought that a larger multicenter experience would have been 
useful to add more data about this methodology and its impact on procedural outcome.  
 
METHODS 
All paroxysmal AF patients addressed to three university referral centers ( 1-Città della Salute e 
della Scienza Hospital, Turin, Italy, 2-Cardinal Massaia Hospital, Asti, Italy, 3-San Eugenio 
Hospital Rome, Italy) for first AF ablation procedure guided by CARTO3 EAM system (Biosense 
Webster, Diamond Bar, CA) from June 2014 to January 2016 were prospectively enrolled. Each 
patient underwent a TEE before ablation in order to assess the atrial dimensions, rule out the 
presence of thrombi in the left atrium (LA) or in the left atrial appendage (LAA). A contrast-
enhanced magnetic resonance imaging (MRI) of the LA was obtained and merged with the cardiac 
chamber reconstruction performed during the ablation procedure. 
The study protocol was approved by the institutional ethics committee and performed according to 
the principles of the Declaration of Helsinki after written informed consent was obtained from the 
patient. 
Cardiac imaging reconstruction and access to the left atrium 
CARTO3 EAM system, providing real-time visualization of multiple catheters as in a standard 
fluoroscopic view, was used to navigate the venous system and perform a right atrium (RA) 
reconstruction to place all the catheters in the heart. The procedure was performed via both right 
and left femoral veins. Through a venous femoral approach the coronary sinus catheter (Decanav, 
Biosense Webster, Diamond Bar, CA) was advanced in the venous system until RA electrical 




a partial reconstruction of the RA chamber was performed and the catheter was placed inside the 
coronary sinus. An ablation catheter (Smart-Touch, Biosense Webster, Diamond Bar, CA) was then 
carefully advanced through an 8F long sheath in the inferior vena cava up to the RA and an EAM of 
the RA was obtained. Any difficulty in advancing the catheters and navigating the veins was 
overcome by pulling back the catheter and slightly rotating it; during the entire process the catheters 
were constantly visualized. After completion of the 3D EAM of the RA, the patency of the 
foramen ovale was evaluated by pulling back the ablation catheter out of the superior vena cava to 
the RA, mimicking the transseptal maneuver. After reaching the fossa ovalis position on the 
interatrial septum, a gentle pressure was applied to tent the septum itself. If the PFO was present, 
access in the LA was obtained with cautious advancement of the ablation catheter, and an 
appropriate maneuverability of the catheter itself was demonstrated (Figure 1). The catheter was 
subsequently covered in an “over-the-catheter” fashion with the long sheath and then removed, 
leaving the tip of the sheath in the LA. The exact location of the sheath in the LA was assessed by 
the fact that, when the sheath reaches the ablation catheter, the electrodes on the ablation catheters 
turn black (Figure 2). 
The ablation catheter was then reintroduced through the second femoral vein sheath and a second 
attempt to cross the PFO was made in the previously described fashion. In case of failure, the 
mapping catheter (Lasso, Biosense Webster, Diamond Bar, CA) was introduced through the 
transseptal sheath in the LA without fluoroscopy thanks to the possibility of being visualized by 
CARTO3, and the sheath itself was withdrawn in the RA (Figure 3). This expedient enhances the 
possibility of the PFO to be engaged by the ablation catheter because of the smaller size of the 
Lasso catheter shaft (7F) compared to the 8F of the transseptal sheath. 
In case of failure of the previously described approach, a standard transseptal puncture guided by 
fluoroscopy was performed. The transseptal sheath was advanced over-the-wire into the superior 




needle was attached to a pressure transducer. The entire assembly was then withdrawn in left 
anterior oblique view into the RA, paying attention to the needle rotation. When the expected 
position along the interatrial septum was reached, the assembly was 1 mm gently advanced to 
engage the septum itself. The best position was validated in a latero-lateral fluoroscopic view and 
corrected with a clockwise rotation if necessary. The needle was then gently advanced probing the 
septum and access in the left atrium was obtained, confirmed by LA pressure waveform and by LA 
visualization with a small amount of contrast injection. The transseptal sheath was finally advanced 
into the LA and catheter exchange was performed. The ablation catheter was inserted into the LA 
through the same septal hole as previously described (12). 
Regardless the approach used to enter the LA, as soon as the ablation and the Lasso catheters were 
on the left side of the heart, the sheath (flushed with a 0.9% heparinezed NaCl solution) was 
withdrawn again in the RA to reduce the possible risk of embolic events during the procedure. 
After LA access was gained, all the patients underwent an EAM reconstruction by navigating the 
circular mapping and/or the ablation catheter inside the LA and acquiring data points that were 
subsequently interpolated and displayed by the software. The LA MRI reconstruction was merged 
with the EAM and the final reconstruction was obtained. 
In every patient, total procedural time (skin to RA catheter positioning, left atrium access, LA EAM, 
ablation time) and total fluoroscopy time were recorded. 
For each patient, procedural endpoint was PV isolation, demonstrated as disappearance of PV 
potentials on the circular mapping catheter and entrance/exit block when pacing from the LA/PV. 
Radiofrequency (RF) energy was delivered to create a circumferential lesion around the PV antrum 
using maximum power up to 45 W (range 30-45W), temperature cut-off at 43°C, and irrigation rate 
from17 ml/min up to 35 ml/min. 
All patients performed the ablation procedure on warfarin, with a target INR of 2-2.5 the day of the 




third of the total dose soon after venous femoral access and two thirds of the dose after gaining 
access in the LA. After the ablation procedure a transthoracic echocardiography was performed in 
all patients to assess for the presence of pericardial effusion and evaluate the LA function. Patients 
were monitored with continuous ECG recording and were discharged the day after the procedure 
with warfarin therapy for at least 1 month; after 1 month the choice of continuing oral 
anticoagulation depended on individual CHA2DS2-VASc score. Anti-arrhythmic drugs were 
generally discontinued after 3 months, unless continued for other reasons. Patients were followed-
up with a 12-lead ECG, a Holter monitor and a clinical evaluation at 3, 6 and 12 months. Any 
episode of atrial fibrillation of at least 30 s duration occurring after the blanking period of 3 months 
was defined as recurrence. 
Statistical analysis 
Continuous variables are expressed as mean and standard deviations, while categorical variables are 
reported as absolute values and frequencies. Comparison between PFO and standard transseptal 
puncture groups was made with T-Student test for continuous variables and Chi-Square test for 
categorical variables. Kaplan Meier curves were used to measure AF recurrence-free survival over 














Two hundred fifty patients with paroxysmal AF undergoing PVI as first-time procedure were 
prospectively enrolled. Baseline clinical characteristics and echocardiographic data are presented in 
Table 1. In 58 out of 250 (23.2%) patients the LA was accessed through the PFO without the use of 
fluoroscopy. In these patients, no X-ray was used during the entire procedure (to place the catheters 
in the heart, reconstruct the right and LA anatomy, and perform the ablation procedure). In the 
remaining 192 patients a standard fluoroscopy guided transseptal puncture was performed. In 41 out 
of 58 patients, the TEE performed before the ablation procedure, anticipated the presence of a PFO, 
whereas in the remaining 17 cases the PFO was not unveiled by the TEE. In 1 patient the 
preprocedural TEE showed the presence of the PFO, but we were unable to cross it with the 
ablation catheter; therefore a transseptal puncture was performed.  
Pulmonary vein isolation was achieved in all patients (regardless the presence of PFO). The 
procedural parameters and times are reported in Table 2. There were no major complications 
related to the procedure in the acute setting or during in-hospital stay or further follow-up. Minor 
procedure related complication occurred: 1 (0.4%) artero-venous fistula occluded with manual 
compression, 2 groin hematoma (0.8%).  All patients accomplished the 3, 6 and 12-month follow-
up with ECG, Holter ECG recording and clinical examination. To the mean follow up of 12 months 
freedom from AF was 84.5% (49/58) in the PFO group and 82.3% (158/192) in the general AF 
cohort (Figure 4). In particular, 68% (39/58) in the PFO group and 65% (125/192) in the general AF 










The recent implementation of EAM systems to guide ablation procedures has led to a great impact 
in the field of reducing fluoroscopy without lowering clinical outcomes or increasing complications 
(12). AF ablation has always been considered a complex procedure requiring longer fluoroscopy 
times than other types of ablation. One of the greatest impacts in minimizing or eliminating 
fluoroscopy might be represented by the prevention of malignancies, since the absolute lifetime risk 
of fatal cancer increases by 0.05% for every 10 mSV of effective X-ray dose in the adult population 
(15). Moreover, children, women and obese patients are at even higher risk (16,17). Obesity is 
strictly related to AF and obese patients receive more than twice the effective dose compared to 
normal weight patients (18). Many EP laboratories worldwide have started to follow the ALARA 
concept of minimizing x-ray exposure not only to protect the patient but also for the medical staff 
(19). In fact harmful biological effects increased directly with radiation dose. Therefore it is 
essential to reduce the exposure dose to the minimum necessary without forcing to zero-fluoro at 
any cost. Interventional cardiologists, nurses and laboratory technicians who use fluoroscopy on a 
daily bases are exposed indeed to the cumulative risk of radiations. This is even more important in 
high volume centers, where AF ablation is routinely performed. Moreover, among staff that wears 
protective lead aprons, orthopedic problems such as spine, hip, knee and ankle injuries are 
extremely common (20). Our previous experience already demonstrated that reducing fluoroscopy 
was feasible and safe, with only 2 minutes of X-ray necessary to perform the transseptal puncture 
(13). 
The literature reports few studies showing the feasibility of performing a fluoroless AF ablation 
procedure. However, in these initial experiences, ICE was the crucial element, essential for 
fluoroscopy elimination. In a study from Reddy et al. (21), 20 consecutive patients with paroxysmal 
AF underwent zero X-ray ablation with an acute success rate of 97%. They combined the EnSite 




Ferguson et al. (22). They were able to perform a zero-fluoroscopy ablation in 19 out of 21 patients, 
whereas in 2 patients 2-16 minutes of fluoroscopy were needed to facilitate the transseptal puncture. 
Kuhne et al (14), considering a small sample size, reported a totally fluoroless AF ablation 
procedure in 87% of PFO patients guided by Carto3 mapping system. This study demonstrated a 
new method to cross the interatrial septum and position all catheters in the LA in patients with PFO 
completely without fluoroscopy and without additional tools like ICE to assist the AF ablation 
procedure. Our study strongly enhances these results. To the best of our knowledge this is the 
largest experience ever published on this topic. In our experience, we were able to handle without 
problems both the ablation and the circular mapping catheter inside the LA with a good 
maneuverability, despite entering the chamber through the PFO; in no case bringing the sheath in 
the LA to confer more stability to the ablation catheter was necessary, thus reducing the risk of 
embolization. 
Besides feasible, our approach seemed safe as well; no major complications were observed in the 
acute setting or during follow-up. Indeed, the presence of the long sheath into the LA is identifiable 
thanks to the EAM system: the exact location is revealed by the progressive color change of the 
ablation catheter electrodes once the sheath covers it (Figure 2). Moreover, catheter shape and 
visualization with CARTO3 EAM is reliable as already demonstrated in our previous paper (13). 
We have also to consider that, theoretically, every time a transseptal puncture is performed, the 
patient has an additional risk of complication. Compared to the group of patients undergoing AF 
ablation with a standard transseptal puncture and thus with the use fluoroscopy, the PFO group 
showed the same effectiveness of PV isolation. Ablation success was 100% in the acute setting in 
both groups and AF recurrence was also similar in the long-term. 
In line with previously published papers, fluoroless ablation does not take more time to be 
performed than standard PV isolation guided by fluoroscopy (7,11,23). In our report, procedural 




transseptal puncture, demonstrating that probing the fossa ovalis and searching or a PFO is a 
feasible and not time consuming operation that can potentially be done in every patient. 
The only discriminating factor to obtain a complete fluoroless AF ablation was the presence and/or 
the capability to cross the PFO. The patency had been found during gentle tenting of the fossa 
ovalis only performed with the ablation catheter at the time of catheter positioning. In our 
experience, this maneuver has been accomplished without affecting the safety of the procedure, and 
an attempt might be considered as part of a standard ablation procedure before proceeding to 
transseptal puncture. However, we have to stress that this maneuver has to be carried out carefully, 
using a contact force enable catheter with a gentle probing of the fossa in order to avoid dissection 
of the inter-atrial septum.  
In fact Lehrmann et al (24) reported a 1.5% complication rate during the insertion of the ablation 
catheter into the LA through the same septal hole of the previous transseptal puncture or crossing 
the PFO. However, in this experience, in all patients the first access to the LA was obtained with a 
transseptal puncture, even when a PFO was present, consequently we may speculate that this 
maneuver may favor inter-atrial septum dissection considering also that the ablation catheters used 




A limitation of the study may be the fact that some possible complications could have been missed 










The presence of a PFO may allow completely fluoroless safe and effective AF ablation. 
This approach does not seem to affect negatively the procedural times, acute and long-term 
outcome. Probing the fossa ovalis looking for the PFO during the procedure is desirable since it is 







 Group A (58 pts) Group B (192 pts) P value 
Mean age (years) 59.7 ± 11.2 59.0 ± 10.5 0.66 
Male Sex  12 F, 46 M 41 F, 151 M 0.92 
BMI  25.1 ± 3.8 24.5 ± 4.1 0.32 
Hypertension 25/58 (43%) 92/192 (48%) 0.62 
Diabetes 3/58 (5%) 18/192 (9%) 0.47 
Hyperlipidemia 9/58 (16%) 35/192 (15%) 0.79 
Previous Stroke/TIA  3/58 (5%) 4/192 (2%) 0.40 
Cha2ds2-Vasc  2.2 ± 0.6 2.3 ± 0.5 0.20 
Antiarrhythmic drugs: 
      -Class Ic AAD 











       -VKA 











   -LA diameter AP (mm) 
   -LA Volume (ml) 
   -Mean EF (%) 
 
46 ± 5.7 
85.1 ± 29.3 
59.7 ± 7.3 
 
45.3 ± 6.1 
89.9 ± 28.0 






F = females; M = males; BMI = body mass index; TIA = transient ischemic attack; AAD = 
antiarrhythmic drug; VKA = vitamin K antagonist, DOAC = direct oral anticoagulant; LA = left 











Total procedural time (min) 88.5 ± 26.7 99.1 ± 30.0 0.15 
Skin-to-catheter positioning time 
(min) 
23.2 ± 11.9 26.8 ± 16.1 0.34 
LA mapping time (min) 16.5 ± 9.5 19.5 ± 9.8 0.20 
PVI radiofrequency delivering time 
(min) 
46.3 ± 12.2 47.7 ± 17.2 0.73 
Fluoroscopy time (min) 0 3.9 ± 1.6 0.0001 
Contact Sensor Force guided 
Procedure (%) 
35 (60.3%) 112 (58.3%) 0.49 
Mean Periprocedural ACT (sec) 298±32 305±38 0.11 
 
PVI = pulmonary vein isolation; LA = left atrium; PFO = patent foramen ovale; ACT = activated 





































Number at risk 
 Baseline 3 months 6 months 12 months 
PFO group 58 58 (1) 57 (4) 53 (4) 







Panel A. The coronary sinus catheter located at the RA-superior vena cava junction, as confirmed 
by the appearance of RA electrical potentials on the catheter’s poles; Panel B. The coronary sinus 
catheter at coronary sinus os (left anterior oblique and right anterior oblique views); Panel C. The 
catheter is placed inside the coronary sinus. Panel D. The ablation catheter is pulled back out of the 
superior vena cava to the RA and reaches the fossa ovalis position on the interatrial septum; Panel 
E. A gentle pressure is applied to tent the septum and access in the LA is obtained through the PFO 
with cautious advancement of the ablation catheter; Panel F. The ablation catheter is withdrawn 
into the RA and an EAM of the crossing pathway is obtained meanwhile. 
 
Figure 2 
All panels show the fluoroscopy image, in the left, and the corresponding Carto3 EAM 
reconstruction 
Panel A. The ablation catheter is located in the LA, crossing the interatrial septum through the PFO 
(Arrows pointing at the ablation catheter exiting the sheath); Panel B. and C. The ablation catheter 
is progressively covered by the long sheath in an “over-the-catheter” fashion. On Carto3 the long 
sheath is not visualized, but the exact location can be established by the disappearance of the 
catheter shaft (Arrows pointing at the ablation catheter exiting the sheath); Panel D. Once the tip of 
the ablation catheter is covered the electrodes on it turn black (Arrows pointing at the ablation 
catheter exiting the sheath). 
 
Figure 3  
Panel A. The ablation catheter is located in the LA, crossing the septum through the PFO, while the 




mapping catheter is located inside the transseptal sheath, at the interatrial septum level; Panel C. 
The circular mapping catheter is deployed in the LA and the sheath is withdrawn in the RA. 
 
Figure 4 
Cumulative atrial fibrillation free survival. Kaplan Meier Curve showing that freedom from AF 
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